Ones To Watch News
Refine Search
Biotechnology
UK-headquartered pharma services and products company Clinigen Group announced it has signed a distribution agreement, with USA-based Deciphera Pharmaceuticals for the supply and distribution of Qinlock (ripretinib) into multiple countries across the globe. 9 February 2022
Biotechnology
German biopharmaceutical contract development and manufacturing organization (CDMO AGC Biologics has expanded its partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, Comirnaty, at the company’s Heidelberg facility. 9 February 2022
Biotechnology
French biotech MaaT Pharma has entered into a partnership agreement with contract development and manufacturing organization (CDMO) Skyepharma to build what to date will be France’s largest specialized cGMP manufacturing facility for ecosystem microbiome-based therapeutics. 9 February 2022
Pharmaceutical
US cancer-focussed firm Karyopharm Therapeutics saw its shares plunge nearly 23% to $7.93 by mid-morning, despite the company releasing a bullish statement on a new trial of its already marketed drug Nexpovio/Xpovio (selinexor) as a treatment for endometrial cancer. 8 February 2022
Biotechnology
Biomunex Pharmaceuticals, a privately-held French biotech focused on providing immuno-therapeutics, and Institut Curie, France’s leading cancer center, today announce a new chapter in their strategic research collaboration. 7 February 2022
Pharmaceutical
The Russian drugmaker Pharmasyntez-Nord is finishing preparations for the commissioning of a second stage of its large-scale production facility in St Petersburg. 7 February 2022
Biotechnology
UK and USA-based biotech firm Orchard Therapeutics’ shares closed up 7.6% and rose a further 4.4% to $1.18 in after-hours trading on Friday, after the company gained clearance for Nation Health Service use in England and Wales for its stem cell therapy Libmeldy (atidarsagene autotemcel). 5 February 2022
Biotechnology
US biopharma firm Mersana Therapeutics’ shot up 9% to $4.67 in early trading, after it announced a research collaboration and license agreement with Janssen Biotech, a part of healthcare giant Johnson & Johnson, to discover novel antibody drug conjugates (ADCs) for three targets. 3 February 2022
Biotechnology
Having been a prolific buyer and licensor of medicines, investigational candidates and companies, including its $64 billion acquisition of Shire in 2018, Japanese drug major Takeda Pharmaceutical is also spinning out assets, some into a newly-formed companies such as Ensoma. 1 February 2022
Biotechnology
Shares of Ionis Pharmaceuticals dropped a relatively modest 5.3% to $30.00 in early trading, as its partner US pharma giant Pfizer said it was pulling out of their collaboration on the ANGPTL3 protein-targeting drug vupanorsen. 31 January 2022
Biotechnology
French biotech Tollys, which is developing the first anti-cancer immunotherapy based on a synthetic Toll-Like Receptor 3 (TLR3) specific agonist, today announces that it has renewed and extended its research collaboration started in 2020 with an unnamed pharmaceutical company, described as “a leader in immuno-oncology.” 31 January 2022
Biotechnology
London-listed Irish infectious diseases specialist Poolbeg Pharma today confirmed that it has signed the licence deal for AnaBio Technologies’ microencapsulation and nanoencapsulation technologies to develop an oral vaccine delivery platform. 31 January 2022
Biotechnology
Shares of Finnish clinical-stage biopharma Faron Pharmaceutical were up 4.7% at 254 pence this morning as it announced the appointment of Juho Jalkanen as chief operating officer of the company. 31 January 2022
Pharmaceutical
French ophthalmology specialist Laboratoires Théa has signed an agreement to purchase seven branded ophthalmic products from Akorn Operating Company. 31 January 2022
Biotechnology
Aurealis Therapeutics, a Swiss-Finnish synthetic biology and China-based Xbiome, an AI-based microbiome drug development company, on Friday announced that they have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational diabetic foot ulcer (DFU), other chronic wounds, and inflammatory disease therapy AUP-16 in Greater China. 29 January 2022
Biotechnology
Following approval of its drug by the US Food and Drug Administration in December, Swedish biotech firm Calliditas Therapeutics today announced the commercial availability and initial sales of Tarpeyo (budesonide), the first and only FDA approved treatment for the immunoglobulin A nephropathy (IgA) patients at risk of disease progression. 28 January 2022
Biotechnology
Clinical-stage gene therapy company MeiraGTx Holdings says it has received a $30 million payment from Janssen Pharmaceuticals, part of US healthcare giant Johnson & Johnson, for a clinical milestone in the Phase III Lumeos trial of botaretigene sparoparvovec (AAV-RPGR), an investigational gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP). 27 January 2022
Biotechnology
Germany-headquartered biotech atai Life Sciences saw its shares rise 3.9% to $5.77 this morning, after announcing the launch of Invyxis, a new, wholly-owned platform company committed to developing new chemical entities (NCEs) and to further pioneering next-generation mental health treatments. 27 January 2022
Biotechnology
T-cell immunotherapy developer Atara Biotherapeutics has entered into a long-term strategic agreement with Fujifilm Diosynth Biotechnologies (FDB), a subsidiary of FUJIFILM Corporation (Fujifilm) under which Fujifilm will acquire Atara’s T-Cell operations and manufacturing (ATOM) facility in Thousand Oaks, California for $100 million upfront, retaining current manufacturing and quality staff at the site. 27 January 2022
Biotechnology
US biotech firm Orgenesis today announces it has achieved its latest milestone in the second phase of its collaboration with the Hospital Infantil Universitario Nino Jesus (Hospital) in Madrid, Spain. 27 January 2022
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze